Company Overview

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.

Read More Corporate Presentation Corporate Fact Sheet

Latest News

IMUNON’s VP of R&D to Present at the Vaccines Summit-2023

November 14, 2023

IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update

November 14, 2023

IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023

November 7, 2023

Financial Events

Imunon’s Third Quarter 2023 Financial Results

November 14, 2023 at 10:00 AM EST

H.C. Wainwright 25th Annual Global Investment Conference

September 11, 2023